- Home
- GLUE vs CNMD Comparison
GLUE vs CNMD Comparison
Compare GLUE & CNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | CNMD |
|---|---|---|
| Founded | 2019 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2021 | 1987 |
Fundamental Metrics
Financial Performance| Metric | GLUE | CNMD |
|---|---|---|
| Price | $21.17 | $38.81 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 6 |
| Target Price | $29.50 | ★ $53.67 |
| AVG Volume (30 Days) | ★ 2.6M | 578.8K |
| Earning Date | 03-19-2026 | 01-28-2026 |
| Dividend Yield | N/A | ★ 1.52% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.25 | ★ 2.05 |
| Revenue | $181,538,000.00 | ★ $1,347,470,000.00 |
| Revenue This Year | $84.02 | $6.81 |
| Revenue Next Year | N/A | $0.93 |
| P/E Ratio | $91.51 | ★ $19.31 |
| Revenue Growth | ★ 1112.27 | 4.61 |
| 52 Week Low | $3.50 | $38.32 |
| 52 Week High | $25.77 | $74.70 |
Technical Indicators
Market Signals| Indicator | GLUE | CNMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 37.69 |
| Support Level | $22.05 | $40.69 |
| Resistance Level | $23.29 | $42.67 |
| Average True Range (ATR) | 1.44 | 1.72 |
| MACD | -0.34 | -0.30 |
| Stochastic Oscillator | 1.29 | 4.73 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.